Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol for fistula closure in Crohn's disease
NCT00354367Phase 3Withdrawn
- Sponsor
- UCB
- Start
- Jan 2007
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
Phase 3, randomised, open-label trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Proportion of patients with fistula improvement at 16 weeks. Planned start Jan 2007; status: withdrawn.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00354367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354367.